Summary
The biliary excretion of mebendazole has been investigated in two patients to whom it was given for the treatment of echinococcosis, although it was found to be only partly effective. Oral mebendazole was extensively metabolized and the conjugated parent substance and its metabolites were excreted in the bile. One patient without cholestasis and with normal liver function had an apparent total biliary clearance (776 ml/min) which approached the hepatic plasma flow. The other patient with cholestasis and impairment of the hepatic drug metabolizing capacity showed a drastically reduced apparent total biliary clearance of 3.8 ml/min. The average plasma level of mebendazole was significantly lower in the former and higher in the latter patient (0.06 and 0.91 nmol/ml, respectively). The data suggest that impaired metabolism and/or biliary elimination can account for the higher plasma mebendazole level in patients with liver damage.
Similar content being viewed by others
References
Allan RJ, Goodman HT, Watson TR (1980) Two high-performance liquid chromatographic determinations for mebendazole and its metabolites in human plasma using a rapid SEP PAK C 18 extraction. J Chromatogr 183: 311–319
Witassek F, Bircher J (1983) Chemotherapy of larval echinococcosis with mebendazole: Microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol 25: 83–88
Michiels M, Hendriks R, Thijssen J, Heykants J (1978) A sensitive radioimmunoassay for mebendazole (R 17635) and flubendazole (R 17889). Janssen research products information service. Preclinical Research Reports Nos. R 17635/11 and R 17889/9
Richardson PDI, Withrington PG (1981) Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology 81: 159–173
Dawson M, Allan RJ, Watson TR (1982) The pharmacokinetics and bioavailability of mebendazole in man: A pilot study using 3H-mebendazole. Br J Clin Pharmacol 14: 453–455
Abshagen U, von Grodzicki U, Hirschberger U, Rennekamp H (1977) Effect of enterohepatic circulation on the pharmacokinetics of spironolactone in man. Naunyn-Schmiedeberg's Arch Pharmacol 300: 281–287
Bell GD, McMullin J, Doran J, Oliver J, McAllister J, Ins F, Monks A, Richens A (1978) Ioglycamide (Biligram) studies in man — plasma binding, renal and biliary excretion studies in jaundiced and anicteric patients. Br J Radiol 51: 251–256
Bircher J, Küpfer A, Gikalov I, Preisig R (1976) Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 20: 484–492
Brugmans JP, Thienpont DC, Van Wijngaarden I, Vanparijs OF, Schuermans VL, Lauwers HL (1971) Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1 278 subjects. J Am Med Assoc 217: 313–316
Author information
Authors and Affiliations
Additional information
Studies were carried out in cooperation with the Swiss Echinococcosis Study Group (Coordinators: A. Akovbiantz, R. Ammann, J. Bircher and J. Eckert)
Rights and permissions
About this article
Cite this article
Witassek, F., Allan, R.J., Watson, T.R. et al. Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. Eur J Clin Pharmacol 25, 81–84 (1983). https://doi.org/10.1007/BF00544020
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544020